Κλινικές μελέτες Πανεπιστημιακής Παθολογικής Κλινικής-Ηπατογαστρεντερολογικής Μονάδας

Κύριος Ερευνητής: Ελευσινιώτης Ιωάννης
1404-0043
“Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose ranging, placebo-controlled pase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatitis (nash) and fibrosis.”

Κύριος Ερευνητής: Ελευσινιώτης Ιωάννης
MO42541
” A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with atezolizumab and bevacizumab.”

Κύριος Ερευνητής: Ελευσινιώτης Ιωάννης
19244
“Regorafenib observational study in hepatocellular carcinoma.”